CAR-T在食管鳞状细胞癌治疗中的研究进展

Research progress of CAR-T in the treatment of esophageal squamous cell carcinoma

嵌合抗原受体T细胞(CAR-T)疗法作为近几年发展迅速的治疗手段,在血液肿瘤治疗中取得了显著的效果,但在食管鳞状细胞癌等实体瘤的治疗中因多种因素而受到限制。明确CAR-T疗法受限制的原因并寻求其应对方法,可为食管鳞状细胞癌的治疗提供新的思路和见解。

Chimeric antigen receptor T cell(CAR-T)therapy,an emerging immunotherapy,has achieved remarkable results in the treatment of hematologic tumors.However,it's limited in the treatment of solid tumors such as esophageal squamous cell carcinoma due to various factors.Clarifying the reasons for the limitation of CAR-T therapy and exploring the corresponding solutions can provide new ideas and insights for the treatment of esophageal squamous cell carcinoma.